|
PDSS1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.30089999778238E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.43409999992161E-07 |
| Normal-vs-Stage2 |
1.630260E-02 |
| Normal-vs-Stage3 |
7.16850000470615E-08 |
| Normal-vs-Stage4 |
5.19850051894366E-10 |
| Stage1-vs-Stage2 |
1.484370E-01 |
| Stage1-vs-Stage3 |
3.646200E-01 |
| Stage1-vs-Stage4 |
4.762400E-03 |
| Stage2-vs-Stage3 |
8.443500E-02 |
| Stage2-vs-Stage4 |
2.160100E-03 |
| Stage3-vs-Stage4 |
4.099600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.0760997061825E-10 |
| Normal-vs-AfricanAmerican |
3.62420000000752E-05 |
| Normal-vs-Asian |
4.839500E-04 |
| Caucasian-vs-AfricanAmerican |
5.896000E-01 |
| Caucasian-vs-Asian |
8.699500E-02 |
| AfricanAmerican-vs-Asian |
8.850100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6850299999982E-05 |
| Normal-vs-Female |
1.79669999988974E-08 |
| Male-vs-Female |
5.232400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.9931999625037E-09 |
| Normal-vs-Age(41-60Yrs) |
1.81510000030194E-07 |
| Normal-vs-Age(61-80Yrs) |
3.94430000000279E-05 |
| Normal-vs-Age(81-100Yrs) |
2.492000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.343200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.428400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.116200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.317600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.255000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.332800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.657200E-01 |
| Classical-VS-Follicular |
2.832000E-02 |
| Classical-VS-Other |
1.125350E-01 |
| Classical-VS-Normal |
4.71909999966158E-09 |
| Tall-VS-Follicular |
1.869430E-01 |
| Tall-VS-Other |
7.481500E-02 |
| Tall-VS-Normal |
1.751800E-04 |
| Follicular-VS-Other |
5.833700E-02 |
| Follicular-VS-Normal |
4.857000E-03 |
| Other-VS-Normal |
1.826560E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.90919999978989E-07 |
| Normal-vs-N1 |
1.32809999997541E-07 |
| N0-vs-N1 |
2.095600E-01 |
|
|
